 |
|
Of Designer Drugs, Magic Bullets, and Gold Standards
Basil M. Rifkind, MD;
Jacques E. Rossouw, MD
JAMA. 1998;279:1483-1485.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
Evaluating the risks and benefits of estrogen and related drugs after menopause is complex given their diverse properties. Major considerations include the effects of such agents on cardiovascular and bone disease; breast and endometrial cancer; the plasma lipoproteins and the blood coagulation system; and hot flashes, vaginal bleeding, breast tenderness, and urogenital function. Some effects may be beneficial, others may be adverse. From these multifaceted and often disparate properties attempts are made to construct a balance sheet to better help select from the available agents those that provide the most benefit and the least harm.1-2 This approach is important in considering the appropriateness of the therapy either for the individual patient or from the standpoint of public health.
Unfortunately, no robust analysis of the benefits and risks can be made at the present time. There is a dearth of the only kind . . . [Full Text of this Article]
From the National Heart, Lung, and Blood Institute, Bethesda, Md.
RELATED ARTICLE
Effects of Raloxifene on Serum Lipids and Coagulation Factors in Healthy Postmenopausal Women
Brian W. Walsh, Lewis H. Kuller, Robert A. Wild, Sofia Paul, Mildred Farmer, Jeffry B. Lawrence, Aarti S. Shah, and Pamela W. Anderson
JAMA. 1998;279(18):1445-1451.
ABSTRACT
| FULL TEXT
|
